Fexofenadine suspension formulation

Details for Australian Patent Application No. 2006326551 (hide)

Owner Sanofi-Aventis U.S. LLC

Inventors Agrawala, Prafulla; Silvey, Gary Lee; Mermey, Matthew; Chrzan, Kazimierz; Tran, Vinh; Porcello, Curtis J.; Haribhakti, Rajiv

Agent Watermark

Pub. Number AU-B-2006326551

PCT Pub. Number WO2007/070517

Priority 60/750,303 14.12.05 US

Filing date 12 December 2006

Wipo publication date 21 June 2007

Acceptance publication date 7 June 2012

International Classifications

A61K 9/16 (2006.01) Medicinal preparations characterised by special physical form - Agglomerates

A61K 31/445 (2006.01) - Non-condensed piperidines, e.g. piperocaine

Event Publications

10 July 2008 PCT application entered the National Phase

  PCT publication WO2007/070517 Priority application(s): WO2007/070517

7 June 2012 Application Accepted

  Published as AU-B-2006326551

4 October 2012 Standard Patent Sealed

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2006326558-Device for converting thermal energy into electrical energy

2006326548-Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors